Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine

By: via Benzinga
Celgene Corporation (NASDAQ: CELG) today announced that results from a multicenter, randomized, placebo-controlled phase II trial ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.